secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0000914475-23-000067
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine settles INGREZZA patent litigation; generic entry delayed to 2040
----------------------------------------------------------------------------

- Settlement with Sandoz and Crystal grants generic INGREZZA license starting Feb 1, 2040, or earlier under certain conditions.
- Patent litigation resolved for one ANDA filer; two other ANDA challenges remain pending with trial set for Jan 2, 2024.
- Agreement to be submitted to FTC and DOJ as required by law.
- INGREZZA is Neurocrine's drug for tardive dyskinesia and Huntington's chorea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000067/0000914475-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000067/nbix-20231005.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer